Eisai hands off responsibility for Aduhelm to Biogen
Summary : –Japanese pharma Eisai has backed away from its 50:50 profit-sharing arrangement with Biogen for troubled Alzheimer’s therapy Aduhelm, handing over…
Summary : –Japanese pharma Eisai has backed away from its 50:50 profit-sharing arrangement with Biogen for troubled Alzheimer’s therapy Aduhelm, handing over…
Summary The U.S. Centers for Medicare & Medicaid Services (CMS) just completed the open comment period for their draft national coverage decision…
Summary – In mid-January, the Centers for Medicare & Medicaid Services (CMS) issued a draft national coverage decision for Biogen’s Alzheimer’s drug…
Summary – The House Energy and Commerce Committee’s health panel met to discuss renewing user fee agreements used to fund the U.S.…
Synopsis: After a special meeting, the Japanese drug reviewers ruled that existing data didn’t support an approval and are therefore seeking additional…
Synopsis: The EMA’s human medicines committee has said it cannot approve Biogen and Eisai’s Alzheimer’s disease therapy Aduhelm, saying it was unconvinced…
Neuland announces that The European Directorate for the Quality of Medicines & HealthCare (EDQM) recently granted a Certificate of Suitability (CEP) for Neuland’s API,…